Boom or bust

5th Feb 2026

Published in PharmaTimes magazine -
The GLP-1 inflection point is a moment of reckoning for us all

Ozempic. Wegovy. Mounjaro. Trulicity. Competing brands. Differing active ingredients and formats. But one huge opportunity.

GLP-1 medications occupy unprecedented territory: prescription products with mainstream consumer awareness, sold everywhere from Costco to aesthetic clinics.

The pace of change and competition in the weight loss category is like nothing we’ve seen before. Already there are new, natural ingredient competitors hitting the market that are not only affordable but taken orally rather than through a jab.

Check out the rest of the feature here

PharmaTimes Magazine

Tags